Labiotech.eu

News and Trends 12 Jun 2023

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including Oxford Science Enterprises, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take Beacon Therapeutics’ development candidates […]

June 12, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction, also found that 39% to […]

June 9, 2023 - 4 minutesmins - By Roohi Mariam Peter

In Depth 9 Jun 2023

Enhancing canine wellness: The promise of immunotherapy for dogs

Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health and extend their lives. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight […]

June 9, 2023 - 8 minutesmins - By Willow Shah-Neville

Podcast 9 Jun 2023

Beyond Biotech podcast 49

This week, we have a conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma. The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the […]

June 9, 2023

News and Trends 9 Jun 2023

Med-Life Discoveries to start rare pediatric disease trial

Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP), which causes significant physical and neurological delays in children who inherit it. Med-Life Discoveries has received a no objection letter (NOL) from Health Canada to begin a phase […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

MOSAIC spatial atlas of cancer cells to be created

Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting. MOSAIC is a $50 million project to revolutionize cancer research through the use […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Astellas developing new gastric cancer drug

Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2023

Quell in potential $2B AstraZeneca cell therapy deal

Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […]

June 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Acepodia raises $100M financing to boost cell therapies

Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […]

June 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 8 Jun 2023

Six companies that have made their name in the cardiovascular space

Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of cardiovascular disease, making up 32% […]

June 8, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 8 Jun 2023

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Enhancing canine wellness: The promise of immunotherapy for dogs

Beyond Biotech podcast 49

Med-Life Discoveries to start rare pediatric disease trial

MOSAIC spatial atlas of cancer cells to be created

Astellas developing new gastric cancer drug

Quell in potential $2B AstraZeneca cell therapy deal

Acepodia raises $100M financing to boost cell therapies

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Six companies that have made their name in the cardiovascular space

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!